Video
Dr. Bilusic on use of the diabetes drug metformin in prostate cancer
Author(s):
Video Player is loading.
Marijo Bilusic, MD, PhD, discusses prior research and next steps with the diabetes drug metformin in patients with prostate cancer. Bilusic is a medical oncologist and GU Site Disease Group Lead, Sylvester Comprehensive Cancer Center, Miami Florida. Prior to starting at Sylvester in 2021, he was an associate research physician at the NCI Medical Oncology Service/Genitourinary Malignancy Branch. Also at the NCI, he served as program director of the NIH Hematology Oncology Fellowship Program.
Related Videos
Study findings highlight gender gaps in oncology authorship and citation
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jim Hu, MD, on urinary continence recovery across RARP techniques
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Special Report: Tips for PCPs on evaluating prostate cancer risk
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
Related Content
